查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1820260

2025 年至 2033 年疫苗佐劑市場規模、佔有率、趨勢及預測（依產品類型、給藥途徑、疾病、應用及地區）

Vaccine Adjuvants Market Size, Share, Trends and Forecast by Product Type, Route of Administration, Diseases, Application, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球疫苗佐劑市場規模達11.07億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到28.517億美元，2025-2033年期間的複合年成長率（CAGR）為10.53%。全球疫苗佐劑市場正在快速成長，原因包括傳染病發病率的上升、免疫學和疫苗技術的重大里程碑、人們對罕見疾病的認知不斷提高、未開發人群對大流行性疫苗接種工作的興趣日益濃厚、政府支出不斷增加以及老年人對有效疫苗接種的需求。

疫苗佐劑市場趨勢：

疫苗和免疫學技術的進步

免疫學在疫苗佐劑開發方面取得了重大進展，新型佐劑比以前認為的更有效、更安全。技術進步使得設計能夠選擇性增強對抗原的免疫反應的佐劑成為可能，這顯著提高了疫苗對抗世界各地多種病原體的能力。最近，在 2024 年 2 月，艾伯維和 Tentarix Biotherapeutics 宣佈建立多年戰略合作夥伴關係，開發腫瘤學和免疫學領域的生物候選藥物。該協議價值超過 6400 萬美元。候選藥物的開發將結合艾伯維在腫瘤學和免疫學方面的能力與 Tentarix 專有的 Tentacles 平台，以發現和開發針對每個醫學分支中一個靶點的條件活性、多特異性生物製劑。這將激活可以調節疾病途徑的免疫細胞，同時減少通常與非特異性治療相關的安全問題。

提高對罕見疾病的認知與理解

人們對罕見疾病的認知不斷提高，這加速了疫苗研發中的獨特挑戰。這種新認知激起了人們對可根據不同利害關係人的特定需求量身定做的疫苗佐劑的興趣。至於歐盟，他們將罕見疾病定義為歐洲人口中每 10 萬人中影響不到 50 人。然而，美國《門診孤兒藥法案》將罕見疾病定義為美國每 10 萬人中影響不到 20 萬人。其他定義包括剛果每 10 萬人中最低為 5 人，而印度每 10 萬人中最高為 76 人。平均而言，全球每 10 萬人中就有 40 人患有罕見疾病。最近，根據 3,585 名罕見疾病患者的數據，罕見疾病的盛行率為世界人口的 3.5% 至 5.9%，相當於 2.63 億至 4.46 億人。

全球推動疫苗接種，因應流行病威脅

以COVID-19為代表的流行病威脅的對抗引發了一場前所未有的全球疫苗接種運動，使疫苗佐劑市場成為公共衛生重點關注的焦點。此外，疫苗佐劑的主要用途是增強免疫反應、提高疫苗穩定性、提高疫苗效力和減少疫苗劑量，這反過來又推動了市場的成長。 「根據ABC新聞報道，每週新增15,141例COVID-19住院病例。根據美國疾病控制與預防中心（CDC）的資訊，這與2024年4月初的住院人數大致相同。但這一數字低於2022年1月22日當週（Omicron浪潮期間）每週150,650例美國住院病例的峰值報告美國住院病例。

疫苗佐劑市場區隔：

按產品類型細分：

  • 佐劑乳劑
  • 病原體成分
  • 顆粒佐劑
  • 組合佐劑
  • 其他

佐劑乳液佔據大部分市場佔有率

佐劑乳劑細分市場的發展源自於人們對高效、長效疫苗日益成長的需求。這種需求源自於乳劑佐劑能夠激發強烈而廣泛的免疫反應，使其成為流感和新冠肺炎等複雜疾病疫苗的理想選擇。乳劑佐劑的多功能性以及與多種抗原的兼容性進一步提升了其吸引力。此外，奈米技術的進步改進了這些佐劑的遞送機制，在保持安全性的同時提高了其有效性。持續進行的旨在最佳化乳劑配方的研發工作對於滿足日益成長的疫苗佐劑市場需求至關重要，凸顯了其在未來疫苗開發策略中的關鍵作用。

依給藥途徑分類：

  • 口服
  • 肌肉注射
  • 鼻內
  • 皮下
  • 皮內
  • 其他

肌肉注射是領先的細分市場

肌肉注射細分市場的成長動力源於對需要深層組織滲透才能達到最佳療效的疫苗（例如流感疫苗、破傷風疫苗和新冠肺炎疫苗）日益成長的需求。這種方法之所以受到青睞，是因為它能夠將大量疫苗直接輸送到血液供應豐富的肌肉中，促進更強、更快速的免疫反應。此外，與其他方法相比，肌肉注射途徑因其給藥相對簡便、不適感最小、不良反應風險較低而受到青睞，使其成為全球疫苗接種計畫中廣泛接受的做法。疫苗吸收率的一致性以及支持其有效性的大量歷史資料進一步增強了其應用，突顯了該細分市場的成長。

依疾病分類：

  • 癌症
  • 傳染病
  • 其他

傳染病佔大部分市場佔有率

傳染病細分市場的成長動力源於全球流行病和新興傳染病威脅的日益加劇，凸顯了對有效疫苗的迫切需求。國際旅行、都市化和氣候變遷等因素加劇了傳染病的傳播，因此需要快速開發和部署含有強效佐劑的疫苗。各國政府和國際上為對抗傳染病而採取的舉措，以及在研發方面的大量投入，進一步推動了該細分市場的成長。此外，公眾意識的提高和醫療基礎設施的改善在支持疫苗接種計劃方面發揮著至關重要的作用，從而增加了對用於有效對抗這些疾病的創新疫苗佐劑的需求。

按應用分類：

  • 研究
  • 商業的

研究代表了領先的細分市場

疫苗佐劑市場的研究領域受到日益成長的疫苗需求的推動，這些需求旨在針對更廣泛的病原體（包括新興和再發傳染病）。這種需求與對免疫系統複雜性的日益加深的理解相結合，促使科學家探索能夠引發更強、更持久免疫反應的新型佐劑配方。此外，個人化醫療和針對個人基因組成的疫苗的需求也推動了創新佐劑的探索。生物技術和奈米技術的進步進一步推動了這一領域的發展，使得能夠精確設計下一代佐劑以增強疫苗有效性並最大程度地減少副作用。

按地區分類：

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

北美引領市場，佔據最大的疫苗佐劑市場佔有率

該報告還對所有主要區域市場進行了全面分析，包括北美（美國和加拿大）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告指出，北美是疫苗佐劑最大的區域市場。

北美疫苗佐劑預計將佔據市場主導地位，因為該地區在疫苗研發方面投入了大量資金，旨在應對各種傳染病以及公共和私營部門日益成長的健康問題。該地區擁有疫苗快速核准流程的優勢，鼓勵製藥公司擴大並增加對佐劑技術的投資。此外，北美擁有許多頂尖研究中心的優勢，並與生物技術產業保持著頻繁的合作。因此，這裡是醫療技術和創新的領域。此外，為了提高疫苗的有效性，佐劑的使用也更加重視提高疫苗的有效性和安全性，推動了北美市場的擴張。

（請注意，這只是關鍵參與者的部分名單，完整名單將在報告中提供。）

  • 疫苗佐劑市場的主要參與者正積極參與研發活動，以推出創新且更有效的佐劑配方。這些努力旨在增強疫苗引發的免疫反應，確保對各種傳染病提供更廣泛、更持久的保護，並開發針對癌症等慢性疾病的治療性疫苗。例如，2022年2月，Novavax Inc.宣布其新冠候選疫苗NVX-CoV2373與其專有佐劑Matrix-M聯合使用的III期臨床試驗取得了積極的中期結果。結果顯示，NVX-CoV2373對新冠具有強大的療效，整體有效率超過90%。合作與夥伴關係是一種常見的策略，它整合學術機構、研究組織和生技公司的專業知識，以加速下一代佐劑的開發。此外，這些公司正在投資先進技術，探索新型佐劑物質，包括合成分子和天然化合物，以提高疫苗的有效性和安全性。在企業應對複雜市場環境、將創新產品推向市場的過程中，合規性和快速核准流程也至關重要。透過這些舉措，關鍵參與者正在為全球疫苗佐劑市場的蓬勃發展和發展做出重大貢獻。

本報告回答的關鍵問題

  • 2024年全球疫苗佐劑市場規模是多少
  • 2025-2033年全球疫苗佐劑市場的預期成長率是多少
  • 推動全球疫苗佐劑市場的關鍵因素有哪些
  • COVID-19 對全球疫苗佐劑市場有何影響
  • 根據產品類型，全球疫苗佐劑市場如何分類
  • 根據給藥途徑，全球疫苗佐劑市場如何分類
  • 全球疫苗佐劑市場依疾病類型分類如何？
  • 根據應用，全球疫苗佐劑市場如何分類？
  • 全球疫苗佐劑市場重點區域有哪些
  • 10. 全球疫苗佐劑市場的主要參與者/公司有哪些？

本報告回答的關鍵問題

  • 2024年全球疫苗佐劑市場規模？ 2025-2033年全球疫苗佐劑市場的預期成長率是多少？
  • 推動全球疫苗佐劑市場發展的關鍵因素有哪些？
  • COVID-19 對全球疫苗佐劑市場有何影響？
  • 根據產品類型，全球疫苗佐劑市場是如何分佈的？
  • 根據給藥途徑，全球疫苗佐劑市場如何分佈？
  • 全球疫苗佐劑市場依疾病分類是怎樣的？
  • 根據應用，全球疫苗佐劑市場是如何分佈的？
  • 全球疫苗佐劑市場的主要地區有哪些？
  • 全球疫苗佐劑市場的主要參與者/公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 二手資料
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球疫苗佐劑市場

  • 市場概況
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依產品類型

  • 佐劑乳劑
  • 病原體成分
  • 顆粒佐劑
  • 組合佐劑
  • 其他

第7章：市場區隔：依行政途徑

  • 口服
  • 肌肉注射
  • 鼻內
  • 皮下
  • 皮內
  • 其他

第 8 章：市場區隔：依疾病

  • 癌症
  • 傳染病
  • 其他

第9章：市場區隔：依應用

  • 研究
  • 商業的

第10章：市場細分：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第 11 章：SWOT 分析

第 12 章：價值鏈分析

第 13 章：波特五力分析

第 14 章：價格分析

第 15 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Adjuvatis
    • Agenus Inc.
    • Croda International Plc
    • CSL Limited
    • Dynavax Technologies
    • InvivoGen
    • Novavax Inc.
    • OZ Biosciences
    • Phibro Animal Health Corporation
    • SEPPIC
    • SPI Pharma
Product Code: SR112025A4385

The global vaccine adjuvants market size reached USD 1,107.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,851.7 Million by 2033, exhibiting a growth rate (CAGR) of 10.53% during 2025-2033. Global vaccine adjuvants market is growing rapidly due to the rising incidence of infectious diseases, significant milestones in immunology and vaccine technology, the escalating awareness of rare disease, the increased interest in pandemic vaccination efforts among the unbuilt population, burgeoning government spending, and the need for effective vaccination for the elderly.

Vaccine Adjuvants Market Trends:

Advancements in Vaccine and Immunology Technology

Immunology has made significant strides in vaccine adjuvant development, with new adjuvants being both more effective and safer than previously thought. Technological progress allows to design adjuvants that can selectively increase immune response to an antigen, which significantly increased vaccines' capability to fight a wide range of pathogens around the world. Recently, in February 2024, AbbVie , and Tentarix Biotherapeutics revealed the multi-year strategic partnership to develop biologic candidates in oncology and immunology. The agreement is valued more than USD 64 million. The drug candidates will be developed to combine AbbVie's capabilities in oncology and immunology with Tentarix's proprietary Tentacles platform to discover and develop conditionally active, multi-specific biologics against one target in each branch of medicine. This will activate immune cells that can modulate disease pathways while reducing the safety concern, typically associated with non-specific treatment.

Rising Awareness and Understanding of Rare Diseases

The growing recognition for rare diseases has accelerated distinctive challenges in the vaccine development. This new awareness has piqued the interest in vaccine adjuvants that can be customized to the specific needs of various stakeholders. As regards to the European Union, they defined RDs as affecting less than 50 per 100,000 people in the European population. However, the American Orphan Drug Act, outpatient, defined RDs as affecting less than 200,000 people in the United States. Other definitions included one as low as 5 per 100,000 people in Congo, while the highest was 76 per 100,000 people in India . On average, RDs affects 40 in every 100,000 people in the world. Recently, the prevalence of Rare Diseases prevalence, based on 3,585 RDs, was between 3.5 to 5.9 percent of the world population, equaling 263 to 446 million individuals.

Global Push for Vaccinations Against Pandemic Threats

The fight against the threat of pandemics, exemplified by COVID-19, sparked an unprecedented global vaccination crusade, propelling the vaccine adjuvants market into the spotlight of priority public health concerns. Moreover, the key uses of vaccine adjuvants are enhancing immune response, vaccine stability, improving vaccine efficiency and reducing vaccines doses, which in turn is propelling the market growth. "There were 15,141 new weekly hospital admissions for COVID-19, according to the ABC news. That's about the same as in early April 2024, according to information from the Centers for Disease Control and Prevention (CDC). But it's not as high as the peak of 150,650 hospitalizations per week for the week of Jan. 22, 2022, during the omicron wave". In total, more than 6 million Americans have been hospitalized over the course of the pandemic, the CDC reports.

Vaccine Adjuvants Market Segmentation:

Breakup by Product Type:

  • Adjuvant Emulsions
  • Pathogen Components
  • Particulate Adjuvants
  • Combination Adjuvants
  • Others

Adjuvant Emulsions accounts for the majority of the market share

The adjuvant emulsions segment is driven by the increasing demand for vaccines with enhanced efficacy and longer-lasting immunity. This interest stems from the ability of emulsion-based adjuvants to provoke a strong and broad immune response, making them ideal for use in vaccines against complex diseases such as influenza and COVID-19. The versatility of emulsion adjuvants, compatible with a wide range of antigens, further boosts their appeal. Additionally, advancements in nanotechnology have improved the delivery mechanisms of these adjuvants, increased their effectiveness while maintaining safety profiles. The ongoing research and development efforts aimed at optimizing emulsion formulations are crucial in meeting the growing vaccine adjuvants market demand, underscoring their pivotal role in future vaccine development strategies.

Breakup by Route of Administration:

  • Oral
  • Intramuscular
  • Intranasal
  • Subcutaneous
  • Intradermal
  • Others

Intramuscular represents the leading market segment

The intramuscular segment is driven by the increasing demand for vaccines that require deep tissue penetration for optimal efficacy, such as vaccines against influenza, tetanus, and COVID-19. This method is preferred for its ability to deliver larger volumes of a vaccine directly into the muscle, where there is a rich blood supply, facilitating a stronger and quicker immune response. Additionally, the intramuscular route is favored for its relative ease of administration, minimal discomfort, and lower risk of adverse reactions compared to other methods, making it a widely accepted practice in vaccination programs globally. The consistency in vaccine absorption rates and the extensive historical data supporting its effectiveness further bolster its adoption, underlining the segment's growth.

Breakup by Diseases:

  • Cancer
  • Infectious Diseases
  • Others

Infectious diseases accounts for the majority of the market share

The infectious diseases segment is driven by the increasing prevalence of global pandemics and emerging infectious threats, which highlight the critical need for effective vaccines. Factors such as international travel, urbanization, and climate change contribute to the spread of infectious diseases, necessitating rapid development and deployment of vaccines with potent adjuvants. The segment's growth is further fueled by governmental and international initiatives to combat infectious diseases, alongside significant investments in research and development. Moreover, public awareness and healthcare infrastructure improvements play essential roles in supporting vaccination programs, thereby enhancing the demand for innovative vaccine adjuvants tailored to combat these diseases effectively.

Breakup by Application:

  • Research
  • Commercial

Research represents the leading market segment

The research segment in the vaccine adjuvants market is driven by the increasing demand for more efficacious vaccines against a broader range of pathogens, including emerging and re-emerging infectious diseases. This need is coupled with a growing understanding of the immune system's complexities, prompting scientists to explore novel adjuvant formulations that can elicit stronger and more durable immune responses. Additionally, the push for personalized medicine and vaccines tailored to individual genetic makeups fuels the exploration of innovative adjuvants. Advances in biotechnology and nanotechnology further drive this segment, enabling the development of next-generation adjuvants that can be precisely engineered to enhance vaccine effectiveness while minimizing side effects.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest vaccine adjuvants market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for vaccine adjuvants.

The North America's vaccine adjuvants are expected to dominate the market due to extensive investment in researching and developing (R&D) vaccines that are aimed at tackling a wide range of infectious illnesses and rising health concerns from both the public and private sectors. The region has the advantage of a rapid approval process for vaccines, which encourages drug companies to expand and boost investments into adjuvant technologies. Furthermore, North America has many of the top research centers superiority and frequent collaboration with the biotech sector. As a result, it is the field of medical technology and innovation. In addition, to improve the effectiveness of vaccines, adjuvants, are used with greater awareness of the importance of boosting the effectiveness and safety of vaccines, driving market expansion in North America.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the vaccine adjuvants industry include Adjuvatis, Agenus Inc., Croda International Plc, CSL Limited, Dynavax Technologies, InvivoGen, Novavax Inc., OZ Biosciences, Phibro Animal Health Corporation, SEPPIC, SPI Pharma, etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • Key players in the vaccine adjuvants market are actively engaging in research and development activities to introduce innovative and more effective adjuvant formulations. These efforts are aimed at enhancing the immune response elicited by vaccines, ensuring broader and more durable protection against a variety of infectious diseases and for therapeutic vaccines targeting chronic conditions such as cancer. For instance, in February 2022, Novavax Inc. announced positive interim results from their Phase 3 clinical trial evaluating their COVID-19 vaccine candidate, NVX-CoV2373, combined with their proprietary adjuvant, Matrix-M. The results showed strong efficacy against COVID-19, demonstrating an overall efficacy of over 90%. Collaborations and partnerships are a common strategy, uniting expertise from academic institutions, research organizations, and biotechnology firms to accelerate the development of next-generation adjuvants. Furthermore, these companies are investing in advanced technologies and exploring novel adjuvant substances, including synthetic molecules and natural compounds, to improve vaccine efficacy and safety profiles. Regulatory compliance and the pursuit of fast-track approval processes are also critical, as companies navigate the complex landscape to bring their innovations to market. Through these actions, key players are significantly contributing to the dynamic growth and evolution of the global vaccine adjuvants market.

Key Questions Answered in This Report

  • 1.What was the size of the global vaccine adjuvants market in 2024?
  • 2.What is the expected growth rate of the global vaccine adjuvants market during 2025-2033?
  • 3.What are the key factors driving the global vaccine adjuvants market?
  • 4.What has been the impact of COVID-19 on the global vaccine adjuvants market?
  • 5.What is the breakup of the global vaccine adjuvants market based on the product type?
  • 6.What is the breakup of the global vaccine adjuvants market based on route of administration?
  • 7.What is the breakup of the global vaccine adjuvants market based on the diseases?
  • 8.What is the breakup of the global vaccine adjuvants market based on the application?
  • 9.What are the key regions in the global vaccine adjuvants market?
  • 10.Who are the key players/companies in the global vaccine adjuvants market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Vaccine Adjuvants Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Adjuvant Emulsions
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Pathogen Components
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Particulate Adjuvants
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Combination Adjuvants
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Intramuscular
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Intranasal
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Subcutaneous
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Intradermal
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Diseases

  • 8.1 Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Infectious Diseases
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Research
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Commercial
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Adjuvatis
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Agenus Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Croda International Plc
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 CSL Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
    • 15.3.5 Dynavax Technologies
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 InvivoGen
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Novavax Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 OZ Biosciences
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Phibro Animal Health Corporation
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 SEPPIC
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
    • 15.3.11 SPI Pharma
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio

List of Figures

  • Figure 1: Global: Vaccine Adjuvants Market: Major Drivers and Challenges
  • Figure 2: Global: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Global: Vaccine Adjuvants Market: Breakup by Product Type (in %), 2024
  • Figure 5: Global: Vaccine Adjuvants Market: Breakup by Route of Administration (in %), 2024
  • Figure 6: Global: Vaccine Adjuvants Market: Breakup by Diseases (in %), 2024
  • Figure 7: Global: Vaccine Adjuvants Market: Breakup by Application (in %), 2024
  • Figure 8: Global: Vaccine Adjuvants Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Vaccine Adjuvants (Adjuvant Emulsions) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Vaccine Adjuvants (Adjuvant Emulsions) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Vaccine Adjuvants (Pathogen Components) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Vaccine Adjuvants (Pathogen Components) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Vaccine Adjuvants (Particulate Adjuvants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Vaccine Adjuvants (Particulate Adjuvants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Vaccine Adjuvants (Combination Adjuvants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Vaccine Adjuvants (Combination Adjuvants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Vaccine Adjuvants (Other Product Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Vaccine Adjuvants (Other Product Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Vaccine Adjuvants (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Vaccine Adjuvants (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Vaccine Adjuvants (Intramuscular) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Vaccine Adjuvants (Intramuscular) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Vaccine Adjuvants (Intranasal) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Vaccine Adjuvants (Intranasal) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Vaccine Adjuvants (Subcutaneous) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Vaccine Adjuvants (Subcutaneous) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Vaccine Adjuvants (Intradermal) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Vaccine Adjuvants (Intradermal) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Vaccine Adjuvants (Other Routes of Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Vaccine Adjuvants (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Vaccine Adjuvants (Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Vaccine Adjuvants (Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Vaccine Adjuvants (Infectious Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Vaccine Adjuvants (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Vaccine Adjuvants (Other Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Vaccine Adjuvants (Other Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Vaccine Adjuvants (Research) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Vaccine Adjuvants (Research) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Vaccine Adjuvants (Commercial) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Vaccine Adjuvants (Commercial) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: North America: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: North America: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: United States: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: United States: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Canada: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Canada: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Asia-Pacific: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Asia-Pacific: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: China: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: China: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Japan: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Japan: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: India: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: India: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: South Korea: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: South Korea: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Australia: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Australia: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Indonesia: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Indonesia: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Others: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Others: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Europe: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Europe: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Germany: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Germany: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: France: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: France: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: United Kingdom: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: United Kingdom: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Italy: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Italy: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Spain: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Spain: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Russia: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Russia: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Others: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Others: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Latin America: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Latin America: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Brazil: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Brazil: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Mexico: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Mexico: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Others: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Others: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Middle East and Africa: Vaccine Adjuvants Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Middle East and Africa: Vaccine Adjuvants Market: Breakup by Country (in %), 2024
  • Figure 89: Middle East and Africa: Vaccine Adjuvants Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 90: Global: Vaccine Adjuvants Industry: SWOT Analysis
  • Figure 91: Global: Vaccine Adjuvants Industry: Value Chain Analysis
  • Figure 92: Global: Vaccine Adjuvants Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Vaccine Adjuvants Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Vaccine Adjuvants Market Forecast: Breakup by Product Type (in Million USD), 2025-2033
  • Table 3: Global: Vaccine Adjuvants Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 4: Global: Vaccine Adjuvants Market Forecast: Breakup by Diseases (in Million USD), 2025-2033
  • Table 5: Global: Vaccine Adjuvants Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 6: Global: Vaccine Adjuvants Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Vaccine Adjuvants Market: Competitive Structure
  • Table 8: Global: Vaccine Adjuvants Market: Key Players